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Abstract
Background: Traditional treatment for motor impairment after stroke includes medication and physical
rehabilitation. The transcranial direct current stimulation associated with a standard physical therapy program may
be an effective therapeutic alternative for these patients.
Methods: This study is a sham-controlled, double-blind, randomized clinical trial aiming to evaluate the efficacy of
transcranial direct current stimulation in activities of daily living and motor function post subacute stroke. In total
there will be 40 patients enrolled, diagnosed with subacute, ischemic, unilateral, non-recurring stroke. Participants
will be randomized to two groups, one with active stimulation and the other with a placebo current. Patients and
investigators will be blinded. Everyone will receive systematic physical therapy, based on constraint-induced
movement therapy. The intervention will be applied for 10 consecutive days. Patients will undergo three functional
assessments: at baseline, week 2, and week 4. Neuropsychological tests will be performed at baseline and week 4.
Adverse effects will be computed at each session. On completion of the baseline measures, randomization will be
conducted using random permuted blocks. The randomization will be concealed until group allocation.
Discussion: This study will investigate the combined effects of transcranial direct current stimulation and physical
therapy on functional improvement after stroke. We tested whether the combination of these treatments is more
effective than physical therapy alone when administered in the early stages after stroke.
Trial registration: NCT02156635 - May 30, 2014. Randomization is ongoing (40 participants randomized as of the
end of December 2015).
Keywords: Transcranial direct current stimulation, Stroke, Rehabilitation, Clinical trial
Background
A stroke is defined as an acute neurological dysfunc-
tion of vascular origin, with sudden development of
clinical signs of brain function disorders, lasting more
than 24 h [1].
In this sense, new therapeutic modalities have been
developed for monitoring patients after a stroke [2].
Simis et al. [3] conducted a placebo-controlled clinical
trial and found that transcranial magnetic stimulation
(TMS) and transcranial direct current stimulation
(tDCS) can cause increased hand motor function com-
pared to placebo stimulation. TMS has been used to
minimize the limitations post stroke, such as functional
independence and motor recovery [4, 5], but it is not
portable/mobile and is expensive. In contrast, tDCS of-
fers some advantages compared to TMS, being portable,
more economical, and easy to operate. The effects are
polarity-dependent, leading to an increase or a decrease
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in cortical excitability [6]. Although some studies have
shown that increasing the current intensity is related to
more robust effects [7], this is also true for adverse
effects such as headache and discomfort under the elec-
trode [8]. Therefore, the maximum current intensity
used is generally 2 mA, and the cortex density varies be-
tween 0.029 and 0.08 mA/cm2 [9]. Animal studies with a
higher current density of 25 mA/cm2 did not induce le-
sions in the brain tissue, meaning that limits well above
those applied in humans did not result in potential ad-
verse effects [10], thereby demonstrating that it is a safe
technique.
There is evidence that repeated sessions of tDCS may
be associated with a longer duration of the behavioral ef-
fects [11]. Monte-Silva et al. [12] demonstrated that the
interval between the sessions can be critical to perform-
ance. The authors found that when an extra session of
tDCS is applied for 1 hour after the first session, the ef-
fects last for a longer time (120 minutes) compared to
the effect of only one or two consecutive sessions, while
an extra session of tDCS applied beyond that period
(that is, 3 hours) did not influence the effect of the first
session. These findings show that studies with the aim of
achieving lasting effects should consider the timing-
dependent plasticity stimulation regulation in the human
motor cortex [13].
Regarding physical therapy, different approaches can
be found for motor recovery, such as mirror therapy
[14], repetitive task practice [15], and robotic training
[16]. However, the type of training that is combined with
stimulation determines how generalizable the benefits
would be. Improvements are specific for tasks that are
strategically paired with stimulation [17].
In this perspective, efforts are currently being made to
standardize the application of the methods that can be
combined with tDCS for the treatment of stroke. Bolog-
nini et al. [18] developed a placebo-controlled trial to in-
vestigate the neuropsychological and behavioral effects
of bihemispheric tDCS (cathodic stimulation in the un-
affected hemisphere and anode in the affected cortex)
combined with a standard physical therapy program
called constraint-induced movement therapy (CIMT)
[19]. The data show that CIMT applied alone only seems
to be effective in modulating cortical excitability, but is
not able to restore the balance of transcallosal inhibition.
According to the authors, bihemispheric tDCS can already
achieve this goal and promote greater functional recovery.
Studies show that CIMT is associated with functional im-
provement in acute and subacute stages of stroke [20–23].
Although most studies in neurostimulation therapy
involve post-stroke patient monitoring for short periods
[24, 25], longitudinal studies would clarify the action
mechanisms and the effective duration of this association
(tDCS plus CIMT) from the early stages of stroke.
The effectiveness of stroke interventions is often de-
scribed by measures of disability, or functional assess-
ment. Evaluations that deal with activities of daily living
(ADLs) generally include the Functional Independence
Measure, the Katz index and the Barthel index (BI), the
latter being a prevalent measure for the clinical evalu-
ation of stroke patients, with substantial supporting re-
search [26–28]. However, there are few studies involving
the ADLs as the primary outcome for a marker of func-
tional recovery after neurostimulation. For example, in a
systematic review where the efficacy of tDCS in ADLs
and motor function after stroke were analyzed, the au-
thors found that the results are inaccurate and the effect
was not sustained when studies of high methodological
quality were included. There were 15 studies involving a
total of 455 participants included, with only randomized
controlled trials and randomized controlled cross-over
trials evaluated. Of the total, the analysis of five studies
involving 286 participants to examine the effects of
tDCS on our primary outcome (ADLs evaluated by BI)
has shown that no effect was observed on the perform-
ance at the end of the intervention. In three studies from
this systematic review involving 99 participants to
evaluate the effects of tDCS in BI scores at the end
of follow-up, evidence suggested an effect on the
ADL performance, but the confidence intervals were
wide, and the effect was not sustained when they only
included studies with low risk of bias. Thus, the au-
thors point to the need for future research in this
area to improve the generalization of the results [29].
Although clinical trials can be found that measure
the efficacy of tDCS in ADLs pointing to positive ef-
fects [30, 31] among other factors, in general they
only include participants in the chronic stage with
brain injuries in different areas and varying levels of
functional incapacity.
Therefore, central questions remain: For a daily proto-
col of 10 days, does the active tDCS applied under a
2 mA current and associated with CIMT have a superior
response to the simulated (placebo) current applied with
CIMT, and if so, what is the size of the effect? What ad-
verse effects are associated with the therapy? Does func-
tional improvement in the ADLs persist over time?
In light of this, a clinical trial phase II/III will be devel-
oped to evaluate the therapeutic effects of tDCS in pa-
tients in the subacute stage after stroke. The purposes
are two: 1) discuss topics related to safety, adverse ef-
fects, feasibility, and effectiveness of tDCS in the treat-
ment of stroke patients; 2) present the work protocol
prior to clinical trial results, ensuring adherence to
protocol. Our hypothesis is that the active stimulation in
the affected hemisphere is more effective than a simu-
lated (placebo) current in activities of daily living in
subacute stroke. Secondly, we are interested in knowing
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whether tDCS is effective in the recovery of the follow-
ing motor variables: spasticity, use of the affected limb,
balance, posture, fall risk, muscle strength, and upper
and lower limb function. Also, we aim to analyze if a
possible functional improvement produces a change in
the patients’ perception of their quality of life. We hope
that the study will contribute to the discussion of the
methodological procedures of clinical trials phase II/III




This is a placebo-controlled, double-blind, randomized
clinical trial (Fig. 1), in which 40 patients are divided
into two groups of 20 participants each. In Fig. 1, the
CONSORT (Consolidated Standards of Reporting Trial)
flowchart [32] shows the number and distribution of
participants: Group A1 - participants in post-stroke sub-
acute stage that receive active tDCS combined with
CIMT; Group A2 - participants in the post-stroke sub-
acute stage who receive a placebo stimulation associated
with CIMT. Patients will undergo three assessments:
baseline (T0), week 2 (T1), and week 4 (T2). Neuro-
psychological tests will be performed at T0 and T2. Ad-
verse events will be measured in each session, where the
researcher responsible for administering the neurostimu-
lation will question the patient on whether they experi-
ence any uncomfortable or painful sensation, and if this
is related to the tDCS, following the procedure of
Brunoni et al. [33]. At the end of the study, participants
who received tDCS and showed clinical improvement
will be invited to receive bimonthly stimulation for
12 months as part of a longitudinal study of tDCS for
stroke. Those who received the tDCS placebo and did
not respond will be invited to receive daily sessions with
an active current for 10 days. Finally, those who had a
response to the placebo will be referred for other phys-
ical therapy treatment.
Patients and enrollment
Participants will undergo neurological, neuropsycho-
logical, and physical therapy evaluation performed by
specialists in each area as the eligibility criteria for
selection.
Inclusion criteria
Patients will be selected according to the following
inclusion criteria: a) age between 18 and 65 years; b)
diagnosis of unilateral, non-recurring, subacute stroke of
ischemic and lacunar type, as defined by the International
Classification of Diseases (ICD-10) through computed
tomography or magnetic resonance imaging conducted by
neurologists; c) a score < 1 on the consciousness and
communication items of the National Institutes of Health
Stroke Scale (NIHSS) [34]; and d) the patient provided
written informed consent.
Although the subacute phase of stroke generally
comprises the period of 7 to 90 days after injury
[35–38], this study will only include those at 1–3
months after stroke to avoid the inclusion of partici-
pants in the acute phase. The definition of the age
group followed the age interval often found in stud-
ies involving tDCS and stroke [17, 39, 40]. However,
for a more conservative position of experimental
control, we preferred to limit the inclusion up to
65 years of age to avoid this variable possibly inter-
fering in the performance of elderly participants, as
this could increase the chances that there are other
conditions associated with aging (such as concentration
and memory).
Exclusion criteria
Patients will be excluded if they have: a) a score between
25–32 points on the NIHSS [34] and grade/degree 5,
according to the Rankin scale [41]; b) cognitive deficits
(a score below 24 points on the Mini Mental State
Examination) [42]; c) an inability to actively carry out
wrist flexing/bending, that is, metacarpophalangeal and
interphalangeal active extension of 10° to 20° wrist
extension.
In addition, exclusion criteria relating to contraindi-
cations of neurostimulation will be applied, following
the safety guidelines [9, 13]: a) use of psychoactive
drugs, as stated in the recommendations; b) patients
with implanted metallic or electronic devices; c) car-
diac pacemaker; d) seizures; e) acute eczema under
the electrodes, the presence of tumors, epilepsy or
substance abuse; f ) pregnancy (this condition was
specifically enlisted as a contraindication in this study
as a precaution, as there are no data on maternal and
fetal effects of tDCS on pregnant women who have
suffered a stroke).
Recruitment
A sample of volunteer participants will be recruited
from hospitals and rehabilitation clinics, linked to the
local public health system, as well as by study informa-
tion provided on websites, newspapers, and radio. There
will also be referred local support groups, outpatient,
and community programs aimed at stroke treatment.
In addition, health professionals from the referred lo-
cations where this study will be performed (hospitals
and rehabilitation clinics) will disseminate the research
among their patients who have suffered stroke. After
prior written consent, patients interested in participating
will have their records analyzed and will be contacted
for inclusion in the study, according to the eligibility
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criteria. Thus, medical records will only be accessed with
prior consent, avoiding possible bias and disregard for
privacy legislation, as pointed out by Kho et al. [43].
Ethics, study registration, and participant consent
The study is being conducted in accordance with the
principles of the Helsinki Declaration [44] and the
guidelines of Good Clinical Practice (GCP) of the Inter-
national Conference on Harmonization of Technical
Requirements for Registration of Pharmaceuticals for
Human Use (ICH) [45]. The study was approved by the
local Ethics Committee of the University of Paraíba
(number 30163714.0.0000.5188; João Pessoa, Brazil),
and is registered in the ClinicalTrials.gov database
(NCT02156635). We followed the SPIRIT (Standard
Protocol Items: Recommendations for Interventional
Trials) guidelines for writing clinical trial protocols [46].
All participating patients will give written informed
consent. During the consent, the researcher clarifies the
objectives and the procedures to be used in research,
with details of the methods to be used, the risks and
benefits, and stating the possibility of inclusion in a
Fig. 1 CONSORT (Consolidated Standards of Reporting Trials) flowchart of the clinical trial. BI: Barthel index; CIMT: constraint-induced movement
therapy; MMSE, Mini Mental State Examination; MoCA: Montreal Cognitive Assessment; MRC: Medical Research Council (scale); NIHSS, National
Institutes of Health Stroke Scale; PASS: Postural Assessment Scale for Stroke; SF-36: Medical Outcomes Study 36-item Short-Form Health Survey;
SPPB: Short Physical Performance Battery; tDCS, transcranial direct current stimulation; WMFT: Wolf Motor Function Test
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control or experimental group. The consent also pro-
vides a full guarantee of freedom for the participant to
refuse to participate or withdraw their consent at any
stage of the research, without any penalty, and shall
maintain the confidentiality and privacy of the partici-
pants during all phases of the research. All participants
will receive a copy of the consent form approved by the
responsible Ethics Committee. To guarantee that all de-
tails of the study process were understood, the researcher
has formulated open questions to ask participants on the
content of the consent, and only those who answer cor-
rectly and sign the document may enter the study.
The study results will be presented at conferences and
published in international peer-reviewed journals regard-
less of the direction and magnitude of the effect.
Outcomes
For analysis of the primary endpoint, the Barthel index
(BI) was chosen because it is commonly used in studies
related to post-stroke rehabilitation, adequately reflect-
ing clinical practice [47–49]. This instrument is designed
to assess the patient’s level of independence to perform
ten basic life activities: eating, bathing, personal care,
ability to dress themselves, motility, urinary regularity,
bathroom use, chair-bed transfer and vice versa, mobil-
ity, and climbing stairs [50]. The literature on the min-
imal clinically important difference detected by the BI
shows that a change of 2 points is meaningful and
beyond measurement error. This calculation refers to
a modified BI with scores of 0–20 points [51]. Since
the changes in the values of the scores do not affect
other properties of the scale, it is considered equiva-
lent to the original version, with scores of 0–100
points [52]. Thus, taking the original scale used in
this study as a reference, clinical improvement will be
considered as a final score higher than 10 points (T2)
according to the BI, compared to baseline (T0) before
the therapeutic protocol [30].
The BI has been reported with excellent levels of reli-
ability, validity, and adequate responsiveness to change
in several countries [52, 53]. In a study of 121 patients at
four post-stroke period points (14, 30, 90, and 180 days),
the inter-rater reliability using a weighted kappa varied
from 0.53 (adequate) to 0.94 (excellent). The inter-rater
reliability for the total score, calculated using the intra-
class correlation, was 0.94 (excellent). The internal
consistency, calculated using Cronbach’s alpha, was ex-
cellent, varying between 0.89–0.92 [54]. The construct
validity was also confirmed by Wilkinson et al. [55], with
rank correlation coefficients of the BI with the SF-36
(Medical Outcomes Study 36-item Short-Form Health
Survey) subscales being found in patients with their
first-ever stroke varying from r = 0.22 (Role Emotional
subscale) to 0.81 (Physical Functioning Profile subscale).
Secondary outcome measures include the Modified
Ashworth Scale, the 30-item Motor Activity Log, the Bio-
dex Balance electronic platform, the Postural Assessment
Scale for Stroke, the Falls Efficacy Scale, the Medical
Research Council scale, the Short Physical Performance
Battery, the Wolf Motor Function Test, and the SF-36.
The Modified Ashworth Scale, used in semiotic clinics
for spasticity evaluation, evaluates the tone in grades of
0-4 points, and is widely used in clinical practice with
adequate test-retest and inter-rater reliability [56–58].
The 30-item Motor Activity Log measures the
spontaneous use of the affected limb. Each item asks
about the frequency and quality of movement in
daily activities of the paretic upper limb. Scores on
this measure have adequate reliability and validity in
individuals with stroke [59, 60].
The Biodex Balance electronic platform measures the
static and dynamic balance through different levels of
stability, such as anteroposterior and mediolateral. This
instrument is used in several studies involving tDCS ap-
plied to stroke [61, 62].
The Postural Assessment Scale for Stroke (PASS) for
postural control [63] contains 12 items with progressive
levels of difficulty, involving three fundamental postures
(lying, sitting, and standing).
The Falls Efficacy Scale measures the fear of falling in
16 ADLs. The total score can vary from 16 (no concern)
to 64 (extreme concern) [64, 65].
The force scale from the Medical Research Council
(MRC) consists of manual muscle testing, varying
from 0 (no movement is observed) to 5 (normal force
against the total resistance), with a maximum score of
60 points [66].
The Short Physical Performance Battery (SPPB)
consists of three tests that evaluate the static standing
balance, gait speed in normal step, and, indirectly, the
muscle strength of the lower limbs. Each domain var-
ies from 0 to 4 points, and the maximum total score
indicates better physical performance [67, 68]. Gait
velocity is a relevant indicator of function and prog-
nosis after stroke [69], meaning that the SPPB is an
important tool for assessment of lower extremity
motor recovery [70–72].
The Wolf Motor Function Test (WMFT) assesses the
speed of task execution through time, the quality of
movement, and the strength of grip and shoulder flexion
in specific tasks. The WMFT tasks should be filmed
with a camera placed at standard position and distance,
and the score of the tasks are given from video analyzes
[73, 74].
The SF-36, a multidimensional questionnaire to analyze
the state of health, consists of 36 items encompassing 8
components, with a final score of 0 (worst state) to 100
(best state) [75].
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Randomization and blinding
The method of randomization will be a 1:1 per-
muted block randomization generated by a web-based
randomization tool (www.random.org). This sequence will
be done independently and remotely by a blinded investi-
gator who will not have contact with other research proce-
dures. The randomization will be concealed until group
allocation.
After the randomization process, a blind researcher
not involved with the recruitment, data collection, or
intervention will perform the allocation of participants
between the groups. This will be employed by concealed
allocation of sequentially numbered, opaque, sealed en-
velopes, so that the person responsible for allocation will
not have contact with patients or with the work of
others. This envelope will be delivered one day before
the treatment sessions to the researcher responsible for
neurostimulation, who will not be involved with the
other procedures for collection or data analysis.
Participants will not be identified by their real names
and will not be aware of which arm of the study they are
allocated to. When included in the study, they will re-
ceive a sealed, opaque envelope containing their respect-
ive identification code. In this way, the assessors will
also be blind, as they will be identifying the patients by
codes and will not have contact with other research pro-
cedures. The same will happen to the staff responsible
for the execution of CIMT procedures. Data analysis will
be conducted by a researcher not involved in any stage
of recruitment, screening, assessment, or intervention.
While evaluating the efficiency of the masking mech-
anism [17], which is routine in studies for the treatment
of stroke and other diseases related to neuromodulation,
biases may occur due to inadequate blinding of several
people involved in the clinical trial, or by error alloca-
tion, the effect of the treatment, or co-interventions
[76]. Unlike blindness, these bias-generating conse-
quences can be measured [77]. To this end, the example
of another study using external judges [78] will be ap-
plied in this work, a final evaluation involving neurolo-
gist doctors accompanying the patients in their clinical
treatment. These professionals will not be aware of be-
havior and interventions applied in this experiment. The
imaging tests carried out for the diagnosis of vascular in-
jury will be repeated and evaluated by these doctors at
the end of intervention (T1) as a routine consultation
procedure. After analysis of these imaging tests, the doc-
tors will be asked whether they believe that the patient
has suffered some consequential event which can act as
an external assessment tool for a clinical trial. Reports of
biased results can be examined as to whether the degree
of agreement between the opinion of an external judge
(neurologist) and the trialists (involved in outcome
assessments and physical therapy interventions with
CIMT) will be the same for both experimental and
control participants.
Intervention
Constraint-induced movement therapy (CIMT)
The CIMT will be held immediately after the patient has
received a neurostimulation session. Daily 3-hour proto-
col motor skills training supervised by a therapist will be
applied for two weeks (10 calendar days, excluding
weekends), with non-affected limb restriction for 90 %
of the patient’s waking time, as advocated in previous
studies with patients after stroke [79]. The motor train-
ing conducted by a physiotherapist will cover the use of
the paretic limb during ADLs, with the non-paretic arm
restricted by a sling. The patient will be encouraged to
use the affected limb during the daily routine of his/her
activities.
Patients will be encouraged to keep a journal to docu-
ment their workouts, recording the training time dur-
ation, activities done with the restriction sleeve, and
main difficulties. The physiotherapist responsible for the
treatment will review the diary weekly, which will allow
for controlling and verifying compliance in the imple-
mentation of CIMT performed by the patient. If there is
a discrepancy with the principles of the technique, ad-
justments and guidelines will be offered for the proper
conduct of the protocol. It is important to clarify that
the purpose of the restriction sleeve is not to encourage
a permanent change in the way the patient performs
daily activities, but to encourage the concentrated and
repetitive use of the paretic upper limb, seeking a “use-
dependent” cortical reorganization [80].
Thus, all participants, regardless of receiving active or
simulated current, will be treated with CIMT during the
10 days of neurostimulation, respecting the ethical prin-
ciples to ensure therapeutic assistance to those involved.
tDCS
The planning of the stimulation variables involves inten-
sity, frequency of sessions, size/position of the elec-
trodes, and duration of treatment [9]. The review of the
therapeutic use of tDCS which defined safety variables
was based on 21 studies (n = 278), and the conditions in-
cluded depression, Parkinson’s disease, cerebral ische-
mia, eating disorders, alcohol dependency, and chronic
pain syndromes. The application of an anodic current
with identical variables to this study (involving the use
of 35 cm2 electrodes and applying a current of 2 mA for
20 minutes for 10 days) was not related to long-term ad-
verse or high magnitude effects [81].
The electrodes are positioned on the participant’s head
at the primary motor cortex area, C3 or C4 position ac-
cording to the electroencephalogram 10–20 system [82].
The anode is placed on the affected hemisphere and the
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cathode (reference electrode) on the supraorbital region
in the uninjured hemisphere [83].
The protocol will be for 20 minutes of stimulation for
10 days (excluding weekends). The TCT neurostimulator
(Research Version) developed by Trans Cranial Research
Limited (Hong Kong, China) will be used, with the kit
containing the neurostimulator, sponges, rubber fas-
teners, electrodes, and connecting cables. Electrodes are
encased with 5 × 7 cm sponges and moistened with sa-
line (0.9 % NaCl). The applied current is 2 mA, with a
relative current density of 0.05 A/m2.
The protocol is identical for placebo stimulation, but
the current will stop after 30 seconds from the start of
stimulation, a blinding method considered reliable for
several previous studies [9, 84], in which the active
current is simulated (slight tingling and itching sensa-
tion) for a short period, and the effects disappear shortly
after the start of the stimulation.
Although the required number and maximum sessions
have not been established, we prefer to follow the model
used in previous studies, which for most cases had con-
secutive sessions of tDCS applied for 10 days, and was
able to improve motor function in different phases of
stroke [24, 85, 86].
Attrition and adherence
Attrition will be considered under the following condi-
tions: a) two consecutive or three alternate absences
during treatment sessions; b) inability to complete the
post-test and follow-up; c) development of any disabling
condition for participation in the study. Regarding adher-
ence strategies, up to two non-consecutive absences can
be compensated the following week. There will also be
flexible hours offered for receiving therapy, as well as dir-
ect contact by telephone with participants confirming the
evaluation dates and reinforcing treatment adherence
[33]. Additional measures to prevent dropouts will also be
applied, such as periodic evaluations (during the outcome
analyses) on satisfaction with therapy, discussion of diffi-
culties in continuing with treatment (for example, trans-
port logistics to the laboratory), and attempts to resolve
and prevent possible problems that may interfere with ad-
herence and continued participation in the study.
Safety
With regards to adverse effects, patients will be asked at
every stimulation session about the effects experienced
such as “tingling,” “burning,” “headache,” “sleepiness,” and
others, which they will then score in intensity (1 -
no, 2 - mild, 3 - moderate, 4- strong), and this effect
is related to the stimulation in a Likert scale of 1 (no
relation) to 5 (strongly related) [33].
Regarding safety, deleterious cognitive effects, that
is any effect from therapy detrimental to cognitive
functions, will be analyzed using the following
neuropsychological tests referenced in the literature:
Montreal Cognitive Assessment (MoCA), which as-
sesses cognitive dysfunction [87]; the Victoria version
of the Stroop Color and Word Test, to measure ex-
ecutive functions [88]; the Digit Span subtest, which
evaluates attention and (direct order) and working
memory (indirect order) [89]. A cognitive evaluation
will be conducted at the beginning and end of the
study to check if there really are deleterious effects
of neurostimulation, so that the values at baseline
can be used as a reference.
We could find no literature reports of any deleterious
cognitive effect after application of tDCS. It is consid-
ered a safe technique that has been used for several
years in post-stroke patient treatment [9, 22, 33, 81].
If the patient experiences any loss or strong dis-
comfort, the treatment will be stopped and medical
care as well as physical and psychological therapy will
be offered for control of potential problems and to
promote recovery.
Data analyses
The design of the statistical analysis is based on previous
studies of literature relating to clinical and placebo-
controlled trials using tDCS [17, 30, 90, 91]. The
intention-to-treat analysis will be used; however, high or
differential rates of missing data between treatment
arms/sides may indicate a departure from this assumption
and may lead to bias [92]. Thus, a sensitivity analysis will
be performed with different allocation procedures to verify
the strength of the data. The best strategy resulting from
the comparison of the following methods will be chosen:
last observation carried forward, complete case analysis,
likelihood-based methods, and multiple imputation [93].
As pointed out by White et al. [94] in the intention-to-
treat analysis strategy, the main focus in the analysis of
choice should be the plausibility of its assumptions, while
the inclusion of all randomized individuals is a require-
ment only for sensitivity analysis.
Multivariate imputation by chained equations (MICE,
the R Foundation for Statistical Computing, Vienna,
Austria) and SPSS Ver.20.0 (SPSS Inc., Chicago, IL, USA)
software will be used.
Regarding sociodemographic and clinical character-
istics at the baseline, for continuous variables, informa-
tion on the variability will be presented for example, mean
and standard deviation). If groups are similar to each
other, descriptive data analysis will be performed. How-
ever, if important differences are found, regression analysis
will be used to evaluate these data to estimate the effects
of covariates with the variables of interest.
Regarding clinical outcomes, the primary outcome will
be analyzed with analysis of mean change scores (MCS)
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to the total score of BI. The MCS will be evaluated in
three ways: change occurred between the post and
pre-test (T1-T0); between endpoint and pre-test (T2-T0);
between the endpoint and post-test (T2-T1). The baseline
as covariate will be used to identify potential differ-
ences between the groups by analysis of covariance
(ANCOVA) [95].
Finally, the effect sizes and confidence intervals of
change scores will be calculated using Cohen’s d, using
the Hedges correction, with values of 0.20, 0.50, and
0.80, reflecting small, medium, and large effects, respect-
ively [96]. For all variables of the secondary outcomes,
the same analysis strategy will be used. Non-parametric
tests will be performed if some of the outcomes do not
meet the conditions necessary for parametric analysis.
Regarding safety, deleterious adverse and cognitive
effects will be recorded/computed in terms of the pro-
portion in each group, in each time period (T0, T1, and
T2), and will be analyzed by the Fisher exact test.
Bias-generating will be tested. The statistical model
used for blinding effectiveness was based on the study of
Brunoni et al. [97]. The chi-square test or Fisher’s exact
test will be used to assess if tDCS blinding guessing was
beyond chance for patients, external judges, and trialists.
Paired t-tests will be used to compare the rate of their
guessing according to the Likert scale. Logistic regres-
sions exploring the factors associated with “correct
blinding guessing” (that is, participants who correctly
guessed their allocation group) will be performed. The
factors will be clinical response, high guessing confi-
dence (scores 4 or 5 on the Likert scale), and adverse
effects.
Sample size
The sample size was estimated based on previous studies
using matched groups of non-invasive stimulation with
rehabilitation [98, 99]. The power calculations to deter-
mine the number of participants in each group were de-
termined in relation to the expected change in BI
because it is commonly used in tDCS studies of patients
after stroke [30, 31].
According to Khedr et al. [30], the mean expected
improvement is about 10 points, with a standard de-
viation (SD) equivalent to 7 points. Thus, a calcula-
tion considering 90 % power suggests that it would
take at least 12 patients in each group to detect the
difference found corresponding to the effect of active
or placebo tDCS.
Considering the possibility of sample loss during the
study (withdrawal, inability to continue the treatment,
mortality), 20 patients will be included per group, total-
ing 40 participants (SPSS Ver.20.0; SPSS Inc., Chicago,
IL, USA). The analysis will be performed at a 0.05
significance level.
Discussion
The present work is a placebo-controlled, double-blind,
randomized clinical trial developed to analyze the effect-
iveness of tDCS in activities of daily living of stroke pa-
tients. Regarding the sample, the majority of clinical
trials involving neuromodulation and rehabilitation in-
volve samples of 20 to 30 subjects and follow-up con-
ducted for approximately three months [17, 100]. The
use of a larger sample, with monitoring of the respon-
dents to therapy during a year as proposed in this study
reduces the risk of type II error, allowing for the possi-
bility of expanding the generalization spectrum into
other contexts related to tDCS.
Furthermore, although other studies have currently
been developed on this subject, most of the work has
methodological differences, such as lack of control on
the type of stroke, lesion location, and characteristics of
the participants [91]. Patients with ischemic stroke
should not be directly compared with those who have
had a hemorrhagic stroke; also, patients with multiple
foci and extensive areas of injury should not be equated
to those with mild or moderate degrees of compromise.
Errors of this nature committed during the inclusion of
the participants are methodological limitations, inhibit-
ing confirmation or refutation of raised hypotheses.
In this sense, questions remain about at what moment
after stroke tDCS therapy would be appropriate. Elsner
et al. [29] developed a systematic review of the applica-
tion of tDCS on motor function and ADLs, and verified
the existence of three studies involving subacute pa-
tients, confirming that most of the work involves pa-
tients analyzed more than six months after the stroke.
Therefore, there is need for controlled clinical trials
evaluating the effect of this technique on patients in the
early stages of a stroke.
As for the therapies associated with neurostimulation,
some studies include patients with tDCS not assisted by
any intervention or uniformed treatment protocols [91,
99]. A Cochrane meta-analysis examined studies using
physical therapy techniques used in post-stroke rehabili-
tation. Although the authors agree that physical therapy
is a key part of rehabilitation, the study’s findings were
not able to measure which technique was more effective
than others. In this sense, the authors recommend that
future research should focus on investigating the effect-
iveness of clearly described techniques and standard
treatments for the tasks developed [29]. Another system-
atic review, which analyzed randomized controlled trials
on the treatment of various therapies involving upper
limbs after stroke, notes that there is a limitation in
terms of scientific evidence of the benefits of conven-
tional therapies such as stretching, passive exercises, and
mobilization [101]. According to the authors, the meth-
odological flaws involving these procedures do not make
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it clear how much therapy is to be provided, who should
provide it, and how patients should be directed so that
the functional gains are maximized.
The lack of control of these techniques with re-
habilitation studies can bring forward biases with con-
founding variables in interpreting the results, beyond
what prevents the replication of future studies in the
area. Techniques not standardized can be considered
inferior to the systematic protocols of physical ther-
apy. Instead, the standard motor training, if coupled
with tDCS, can guide the plasticity process towards a
functional result, since tDCS activates a mass of cir-
cuits which receive neuromuscular feedback in a spe-
cific way [17]. Given these facts, standardized and
systematic CIMT physical therapy was chosen for this
study, taking into account that since the CIMT ther-
apy may promote recovery through inter-hemispheric
inhibition, the tDCS can also induce beneficial effects
of focal mode, activating neural circuits in the dam-
aged hemisphere [18].
Overall, this study will assess the effectiveness of tDCS
combined with CIMT physical therapy protocol in sub-
acute stage after-stroke patients, and analyze the main-
tenance of the benefits achieved over time through
markers of functional recovery. Therefore, the results of
this study may lead to implications for future clinical tri-
als in this area.
Study limitations
Some limitations to our study should be discussed. One
is the adherence. Patients will have to get to the research
center for 10 consecutive days, and therefore there may
be absences due to transportation problems or personal
difficulties. However, different strategies will be adopted
to minimize these problems, such as flexible schedules
and frequent phone contact, encouraging and reinfor-
cing the importance of treatment. Brunoni et al. [33]
had a total of 9 losses after three weeks of stimulation
and 17 at the end of the study (after six weeks), with ap-
plication of similar measures in patients with depression.
These numbers refer to a dropout rate of 7.5 % from
120 patients analyzed. Second, the proposed design does
not include patients with severe functional limitations.
This criterion was inserted because patients with extreme
degrees of disability often exhibit extensive lesions. In
these cases, there is often important impairment of the
corticospinal tract, which could limit the patient to
be chosen for physical therapy protocol, since there is
the requirement of a minimum level of functional
ability to perform the tasks. Accordingly, further stud-
ies on this population could include tDCS treatment
combined with another type of rehabilitation program
with adequate systematization, allowing replication of
the data found.
Trial status
The study was registered at ClinicalTrials.gov on 30 May
2014. Recruitment started on 30 December 2014 and
will proceed until November 2015. Randomization is
ongoing (40 participants randomized as of the end of
December 2015). The final report will be prepared for
2016.
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